Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
With great interest, we read the review article by Agus et al, which suggested that gut microbiome alterations could affect metabolic homeostasis.1 Moreover, gut microbiome alterations in concert with metabolites perturbation could contribute to the early development of rheumatoid arthritis (RA).2 We thus conducted a three-pronged association study3 on multiomics datasets to detect the potential microbiome–metabolites–arthritis link.
We integrated multiomics datasets including gut metagenomics, clinical phenotypes and metabolites of blood and knee-joint synovial fluid from 122 participants in the healthy group (n=27), osteoarthritis (OA) group (n=19) and RA group (n=76), using a three-pronged association framework (figure 1, online supplemental material).3 Metagenomic genes were collapsed into metagenomic species (MGS)3 4 and grouped into KEGG functional modules (figure 1A).3 Additionally, the co-abundant metabolites were categorised into metabolite clusters using WGCNA framework (figure 1A).3 The functional modules associated with clinical phenotypes (eg, types of arthritis and levels of cytokines) were further identified and the cross-domain associations between these modules and metabolite clusters were assessed (figure 1B).3 Furthermore, the leave-one-out analysis was performed to determine the MGS that particularly contributed to the observed linkage between functional modules and clinical phenotypes (figure 1C).3
We found that gut microbial functionality in ascorbate degradation (KEGG module: M00550) was positively correlated with the types of arthritis (healthy=0, OA=1, RA=2, pWilcox=2.15×10–4) and the levels of proinflammatory cytokines TNF-α (tumour necrosis factor-α, pWilcox=6.59×10–4) and IL-6 (interleukin-6, pWilcox=1.12×10–3). Ascorbate (vitamin C) was previously reported to prevent the development of inflammatory arthritis,5 possibly through facilitating collagen synthesis, moderating autoimmune responses and ameliorating inflammation.6 Additionally, the patients with RA are usually ascorbate deficient and require high-dose supplementation to maintain an acceptable plasma level of ascorbate.7 In this study, the functional module of ascorbate degradation was observed to positively correlate with the blood metabolite cluster MB02 (pWilcox=6.90×10–3), which was represented by the level of palmitic acid (kME (eigengene-based connectivity) =0.911, kIN (intramodular connectivity) =3.46, online supplemental table 1) that acts as a proinflammatory factor, upregulating IL-6 secretion by human chondrocytes and fibroblast-like synovial cells in inflammatory arthritis.8 Furthermore, we found that Escherichia coli and Streptococcus bovis were the driving species for the observed linkage between ascorbate degradation9 and the arthritis types or the cytokines levels of TNF-α and IL-6 (figure 1C). Subsequently, we grouped patients with RA by four stages according to the comprehensive scores in rheumatoid diagnostic criteria,10 as RASI: 6–7, RASII: 8, RASIII: 9 and RASIV: 10 (online supplemental table 2). We observed that both E. coli and S. bovis were prevalent at RA stage I (RASI), while S. bovis was depleted after RASI or in the OA group. It suggested S. bovis mainly functioned at the early stage of RA, while E. coli might be crucial throughout the entire developmental stages of RA and OA. Taken together, we speculate that E. coli and S. bovis could facilitate ascorbate degradation and thus promote proinflammatory responses that facilitate the development of inflammatory arthritis.
Overall, we demonstrate that gut microbiota could promote RA progression via enhancing ascorbate degradation and provide a potential approach to prevent the development of arthritis through interfering gut–joint axis. The results of this study could be prospected in following contexts: First, our study provides a reservoir of the potential microbiome–metabolites–arthritis links as a reference of gut–joint axis for future studies. Second, the findings supplement the potential mechanisms related to metabolic perturbation through which gut microbiome promotes arthritis.1 2 Third, considering the inflammatory pathways of arthritis were revisited in COVID-19,11 it deserves further investigations whether microbiome–ascorbate–inflammation link of this study could contribute to the treatment of COVID-19.
Patient consent for publication
The study was approved by the Ethics Committee of the First Affiliated Hospital of Shandong First Medical University (No. 2017-02).
YZ and MC contributed equally.
Correction notice This article has been corrected since it published Online First. The figure has been replaced for clarity.
Contributors YZ and MC designed the study, conducted the data analysis and wrote the manuscript. YZ, MC, LZ, LY, CZ, YZ and XZ collected the samples, conducted the experiments and participated in data analysis. LZ, KN and JH supervised the study and revised the manuscript.
Funding This study was funded by National Natural Science Foundation of China (grant numbers 32071465, 82003766, 31871334, and 31671374), Academic Promotion Project of Shandong First Medical University (grant number 2019LJ001) and Ministry of Science and Technology’s National Key Research and Development Programme (grant number 2018YFC0910502).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.